Drug for adults with NF1 and non-surgically treatable nerve tumors
Part of Brain & nervous system, Cancer, Genetic & congenital clinical trials.
This Phase 2 trial tests HL-085 in adults with neurofibromatosis type 1 (NF1) who have a nerve tumor (plexiform neurofibroma) that cannot be removed by surgery and causes symptoms. It aims to shrink or control the tumor by measuring changes on MRI and monitoring side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re at least 18 years old when the study starts.
- You have NF1 and a plexiform neurofibroma that cannot be removed by surgery and is causing symptoms.
- You have an NF1 diagnosis by genetic mutation or by meeting at least one NF1 sign (like many café-au-lait spots, certain eye findings, specific bone changes, or an NF1 first-degree relative).
- You have a measurable plexiform neurofibroma lesion (at least 3 cm) that can be checked with MRI.
- You can do study visits and follow-up, and your general functioning is good (ECOG 0 to 2).
- You can swallow and take pills by mouth, and you can safely have MRI scans.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows up with children who took part in an earlier trial of FCN-159, a drug for a condition called Neurofibromatosis Type 1 (NF1). It aims to see how safe and effective the drug is over a longer period.
This study tests whether the drug selumetinib can prevent the growth of plexiform neurofibromas (nerve tumors) in young children with NF1. Children are first monitored with MRI scans, and if a tumor appears or grows, they may receive treatment.
This trial tests a combination of two targeted drugs (cabozantinib and selumetinib) for people with NF1 who have plexiform neurofibromas that are growing or causing significant problems. The goal is to see if this combination can shrink or slow the growth of these tumors.
This trial tests a daily capsule called semetinib for adults with type 1 neurofibromatosis (NF1) who have at least one measurable tumor. It aims to shrink or slow tumor growth, especially for tumors that can be surgically removed.
This trial tests an investigational drug called smethinib (a type of targeted therapy) for people with neurofibromatosis type 1 whose tumors have grown into the brain, spine, or other important organs and cannot be removed by surgery. The goal is to see if the drug can shrink or slow the growth of these tumors.
This trial studies whether the medicine abemaciclib can shrink or slow the growth of “atypical neurofibromas” in people with NF1. Participants take pills and undergo regular check-ups, including MRI scans to measure the tumor.
Hear when a new Neurofibromatosis 1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.